Research programme: recombinant human serum albumin biosimilar - Biogenomics

Drug Profile

Research programme: recombinant human serum albumin biosimilar - Biogenomics

Latest Information Update: 28 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biogenomics
  • Class Plasma expanders
  • Mechanism of Action Protein replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Hypoalbuminaemia; Hypovolaemia

Most Recent Events

  • 28 Feb 2018 No recent reports of development identified for research development in Hypoalbuminaemia in India (IV, Infusion)
  • 28 Feb 2018 No recent reports of development identified for research development in Hypovolaemia in India (IV, Infusion)
  • 16 Jan 2014 Research programme: recombinant human serum albumin biosimilar - Biogenomics is available for licensing in World as of 16 Jan 2014. http://www.biogenomics.co.in
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top